Diagnostic performance of whole body dual modality 18F-FDG PET/CT imaging for N- and M-staging of malignant melanoma: Experience with 250 consecutive patients

Journal of Clinical Oncology

Volumn 24, Issue 7, 2006, Pages 1178-1187

  Reinhardt, Michael J ^a   Joe, Alexius Y ^a   Jaeger, Ursula ^a   Huber, Andrea ^a   Matthies, Alexander ^a   Bucerius, Jan ^a   Roedel, Roland ^a   Strunk, Holger ^a   Bieber, Thomas ^a   Biersack, Hans Juergen ^a   Tüting, Thomas ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; ARTICLE; CANCER STAGING; CLINICAL TRIAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MELANOMA; PRIORITY JOURNAL; VISCERAL METASTASIS; WHOLE BODY IMAGING; AGED; MIDDLE AGED; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; RADIOGRAPHY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; SKIN TUMOR;

ADULT; AGED; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; SKIN NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 33644975843     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.03.5634     Document Type: Article

References (34)

1. Thompson JF, Scolyer RA, Kefford RF: Cutaneous melanoma. Lancet 365:687-701, 2005
2. Jemal A, Tiwari RC, Murray T, et al: American Cancer Society. Cancer statistics, 2004. CA Cancer J Clin 54:8-29, 2004
3. Breslow A: Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 172:902-908, 1970
4. Balch CM, Soong SJ, Gershenwald JE, et al: Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 19:3622-3634, 2001
5. Balch CM, Buzaid AC, Soong SJ, et al: Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19:3635-3648, 2001
6. Day CL Jr, Sober AJ, Lew RA, et al: Malignant melanoma patients with positive nodes and relatively good prognoses: Microstaging retains prognostic significance in clinical stage I melanoma patients with metastases to regional nodes. Cancer 47:955-962, 1981
7. Kern KA: [14C]deoxyglucose uptake and imaging in malignant melanoma. J Surg Res 50:643-647, 1991
8. Wahl RL, Hutchins GD, Buchsbaum DJ, et al: 18F-2-deoxy-2-fluoro-D-glucose uptake into human tumor xenografts: Feasibility studies for cancer imaging with positron-emission tomography. Cancer 67:1544-1550, 1991
9. Gambhir SS, Czernin J, Schwimmer J, et al: A tabulated summary of the FDG PET literature. J Nucl Med 42:1S-93S, 2001 (suppl)
10. Friedman KP, Wahl RL: Clinical use of positron emission tomography in the management of cutaneous melanoma. Semin Nucl Med 34:242-253, 2004
11. Prichard RS, Hill AD, Skehan SJ, et al: Positron emission tomography for staging and management of malignant melanoma. Br J Surg 89:389-396, 2002
12. 18F]fluorodeoxyglucose positron emission tomography in melanoma patients. Cancer 91:1530-1542, 2001
13. Tsao H, Atkins MB, Sober AJ: Management of cutaneous melanoma. N Engl J Med 351:998-1012, 2004
14. Miranda EP, Gertner M, Wall J, et al: Routine imaging of asymptomatic melanoma patients with metastasis to sentinel lymph nodes rarely identifies systemic disease. Arch Surg 139:831-836, 2004: discussion 836-837
15. Antoch G, Vogt FM, Freudenberg LS, et al: Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology. JAMA 290:3199-3206, 2003
16. Antoch G, Saoudi N, Kuehl H, et al: Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: Comparison with CT and PET. J Clin Oncol 22:4357-4368, 2004
17. Beyer T, Antoch G, Blodgett T, et al: Dual-modality PET/CT imaging: The effect of respiratory motion on combined image quality in clinical oncology. European Journal of Nuclear Medicine and Molecular Imaging 30:588-596, 2003
18. Kinahan PE, Hasegawa BH, Beyer T: X-ray-based attenuation correction for positron emission tomography/computed tomography scanners. Semin Nucl Med 33:166-179, 2003
19. Tyler DS, Onaitis M, Kherani A, et al: Positron emission tomography scanning in malignant melanoma. Cancer 89:1019-1025, 2000
20. Finkelstein SE, Carrasquillo JA, Hoffman JM, et al: A prospective analysis of positron emission tomography and conventional imaging for detection of stage IV metastatic melanoma in patients undergoing metastasectomy. Ann Surg Oncol 11:731-738, 2004
21. Stas M, Stroobants S, Dupont P, et al: 18-FDG PET scan in the staging of recurrent melanoma: Additional value and therapeutic impact. Melanoma Res 12:479-490, 2002
22. Swetter SM, Carroll LA, Johnson DL, et al: Positron emission tomography is superior to computed tomography for metastatic detection in melanoma patients. Ann Surg Oncol 9:646-653, 2002
23. Fuster D, Chiang S, Johnson G, et al: Is 18F-FDG PET more accurate than standard diagnostic procedures in the detection of suspected recurrent melanoma? J Nucl Med 45:1323-1327, 2004
24. Reinhardt MJ, Wiethoelter N, Matthies A, et al: PET recognition of pulmonary metastases on PET/CT imaging: Impact of attenuation-corrected and non-attenuation corrected PET images. Eur J Nuc Med Mol Imaging 33:134-139, 2006
25. Wagner JD, Schauwecker DS, Davidson D, et al: FDG-PET sensitivity for melanoma lymph node metastases is dependent on tumor volume. J Surg Oncol 77:237-242, 2001
26. Beyer T, Townsend DW, Brun T, et al: A combined PET/CT scanner for clinical oncology. J Nucl Med 41:1369-1379, 2000
27. Macfarlane DJ, Sondak V, Johnson T, et al: Prospective evaluation of 2-[18F]-2-deoxy-D-glucose positron emission tomography in staging of regional lymph nodes in patients with cutaneous malignant melanoma. J Clin Oncol 16:1770-1776, 1998
28. Wagner JD, Schauwecker D, Davidson D, et al: Prospective study of fluorodeoxyglucose-positron emission tomography imaging of lymph node basins in melanoma patients undergoing sentinel node biopsy. J Clin Oncol 17:1508-1515, 1999
29. Belhocine T, Pierard G, De Labrassinne M, et al: Staging of regional nodes in AJCC stage I and II melanoma: 18FDG PET imaging versus sentinel node detection. Oncologist 7:271-278, 2002
30. Havenga K, Cobben DC, Oyen WJ, et al: Fluorodeoxyglucose-positron emission tomography and sentinel lymph node biopsy in staging primary cutaneous melanoma. Eur J Surg Oncol 29:662-664, 2003
31. Garbe C, Paul A, Kohler-Spath H, et al: Prospective evaluation of a follow-up schedule in cutaneous melanoma patients: Recommendations for an effective follow-up strategy. J Clin Oncol 21:520-529, 2003
32. Schaefer NG, Hany TF, Taverna C, et al: Non-Hodgkin lymphoma and Hodgkin disease: Coregistered FDG PET and CT at staging and restaging - do we need contrast-enhanced CT? Radiology 232:823-829, 2004
33. Wong C, Silverman DH, Seltzer M, et al: The impact of 2-deoxy-2[18F] fluoro-D-glucose whole body positron emission tomography for managing patients with melanoma: The referring physician's perspective. Mol Imaging Biol 4:185-190, 2002
34. Harris MT, Berlangieri SU, Cebon JS, et al: Impact of 2-deoxy-2[18F] fluoro-D-glucose positron emission tomography on the management of patients with advanced melanoma. Mol Imaging Biol DOI: 10.1007/s11307-005-0002-7